Hepatitis C Market Report 2026

Hepatitis C Market Overview

• Hepatitis C market size has reached to $75.72 billion in 2025 • Expected to grow to $153.67 billion in 2030 at a compound annual growth rate (CAGR) of 15.4% • Growth Driver: Rising Viral Infections Fueling Advancements In The Hepatitis C Market • Market Trend: Innovation With Dual Antigen And Antibody Diagnostic Test For Early Detection Of Hepatitis C • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hepatitis C Market?

Hepatitis C is a viral infection that primarily affects the liver, leading to inflammation, liver damage, and potentially cirrhosis or liver cancer if untreated. It spreads through contact with infected blood and is treated using antiviral medications aimed at eradicating the virus from the bloodstream. The main types of hepatitis C are chronic hepatitis C, acute hepatitis C, and others. Chronic hepatitis C refers to a long-lasting infection caused by the hepatitis C virus that occurs when the body is unable to fight off the virus. It can be treated by antiviral drugs, vaccines, immune modulator drugs, surgery, and others. The diagnosis process is followed for liver biopsy, blood tests, imaging tests, and others, and is distributed by hospital and retail pharmacies, and online pharmacies. The end-users include hospitals, clinics, ambulatory surgical centers, diagnostic laboratories, research institutes, and home care settings.

What Is The Hepatitis C Market Growth Forecast?

The hepatitis c market size is expected to see rapid growth in the next few years. It will grow to $153.67 billion in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to increasing elimination targets by health organizations, rising investments in hepatitis screening, growing adoption of simplified treatment protocols, expansion of telemedicine-based care, increasing access in emerging markets. Major trends in the forecast period include increasing adoption of direct-acting antivirals, rising focus on early screening programs, growing access to curative treatment regimens, expansion of public health awareness campaigns, enhanced focus on treatment adherence.

Global Hepatitis C Market Segmentation

1) By Type: Chronic Hepatitis C, Acute Hepatitis C 2) By Diagnosis: Liver Biopsy, Blood Tests, Imaging Tests, Other Diagnosis 3) By Distribution Channel: Hospital And Retail Pharmacies, Online Pharmacies 4) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Research Institutes, Home Care Settings Subsegments: 1) By Chronic Hepatitis C: Genotype 1, Genotype 2, Genotype 3, Genotype 4, Genotype 5, Genotype 6 2) By Acute Hepatitis C: Symptomatic, Asymptomatic

What Is The Driver Of The Hepatitis C Market?

An increase in viral infections is expected to propel the growth of the hepatitis C market going forward. Viral infections refer to infections caused by a virus in the body. Hepatitis C treatment reduces viral infection by eradicating viral infection and restoring immune response in hepatitis C patients after viral clearance. For instance, in August 2024, according to the Centers for Disease Control and Prevention, a US-based public health agency, the percentage of individuals with Parvovirus B19, a seasonal respiratory viral infection, increased across all age groups, rising from 3% during 2022–2024 to 10% in June 2024; among them, the most significant rise was seen in children aged 5–9 years, where the prevalence jumped from 15% during 2022–2024 to 40% by June 2024. Also, the proportion of pooled samples containing parvovirus B19 DNA levels has increased significantly from 1.5% in December 2023 to 19.9% in June 2024. Therefore, an increase in viral infections is driving the hepatitis C industry.

Key Players In The Global Hepatitis C Market

Major companies operating in the hepatitis c market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Lupin Limited, Cadila Healthcare Ltd., Biocon Limited

Global Hepatitis C Market Trends and Insights

Major companies in the hepatitis C market are focusing on developing advanced products, such as dual antigen and antibody diagnostic tests, to improve the accuracy and efficiency of early detection and treatment. A dual antigen and antibody diagnostic test detects both the presence of hepatitis C virus (HCV) antigens and antibodies in a patient's blood. For instance, in July 2023, Roche Diagnostics, a Switzerland-based company that develops diagnostic tests, instruments, and digital solutions, launched Elecsys HCV Duo in India. Elecsys HCV Duo is a dual antigen and antibody diagnostic test developed for the simultaneous detection of both the hepatitis C virus (HCV) antigen and antibodies from a single plasma or serum sample. The test's dual detection capability addresses the challenge of asymptomatic early infections, which often go undiagnosed due to the absence of antibodies in the initial stages. By identifying active infections sooner, the Elecsys HCV Duo helps healthcare providers initiate appropriate treatment plans more quickly, potentially reducing disease progression and transmission rates.

What Are Latest Mergers And Acquisitions In The Hepatitis C Market?

In July 2025, Thailand’s Government Pharmaceutical Organization (GPO) formed a partnership with DNDi and Pharco to register an effective and affordable hepatitis C treatment. The collaboration aims to improve access to, and broaden the availability of, high-quality antiviral therapies, enhancing patient outcomes in hepatitis C management while fostering innovation and growth in the global infectious disease treatment market. DNDi is an international non-profit organization dedicated to developing treatments for neglected diseases, and Pharco is an Egyptian pharmaceutical company specializing in the production and distribution of innovative medicines.

Regional Outlook

North America was the largest region in the hepatitis C market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hepatitis C Market?

The hepatitis C market consists of revenues earned by entities by providing shunt procedures, hepatic resection, and biopsies. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis C market also includes sales of ledipasvir and sofosbuvir, non-structural protein 5B (NS5B) polymerase inhibitors, non-structural protein 5A (NS5A) replication complex inhibitors, and elbasvir and grazoprevir drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hepatitis C Market Report 2026?

The hepatitis c market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis c industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.